Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Update
by Jessica Moore · The Cerbat GemMolecular Partners AG Sponsored ADR (NASDAQ:MOLN – Get Free Report) was the recipient of a significant decrease in short interest in December. As of December 15th, there was short interest totaling 20,342 shares, a decrease of 23.0% from the November 30th total of 26,423 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average trading volume of 4,116 shares, the short-interest ratio is currently 4.9 days. Based on an average trading volume of 4,116 shares, the short-interest ratio is currently 4.9 days. Approximately 0.1% of the company’s stock are short sold.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. dropped their target price on shares of Molecular Partners from $4.00 to $3.75 and set a “neutral” rating for the company in a research report on Monday, December 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Molecular Partners in a research note on Monday, December 22nd. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $7.88.
Check Out Our Latest Research Report on MOLN
Molecular Partners Stock Performance
Shares of MOLN traded down $0.13 during midday trading on Tuesday, hitting $4.30. 4,297 shares of the stock traded hands, compared to its average volume of 4,163. The business’s 50 day moving average price is $4.16 and its two-hundred day moving average price is $3.87. The firm has a market capitalization of $173.63 million, a PE ratio of -2.24 and a beta of 1.08. Molecular Partners has a 1-year low of $3.36 and a 1-year high of $5.91.
Molecular Partners (NASDAQ:MOLN – Get Free Report) last issued its quarterly earnings data on Thursday, October 30th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.05. As a group, equities research analysts forecast that Molecular Partners will post -1.93 EPS for the current fiscal year.
About Molecular Partners
Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.
The company’s development pipeline spans infectious diseases, ophthalmology and oncology.